Barclays
DNA icon

Barclays’s Ginkgo Bioworks DNA Stock Holding History

Barclays’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$6.56M Buy
511,416
+481,450
+1,607% +$3.92M ﹤0.01% 1894
2026
Q2 		$297K Buy
29,966
+21,988
+276% +$184K ﹤0.01% 3501
2026
Q1 		$48.9K Sell
7,978
-56,487
-88% -$470K ﹤0.01% 4329
2025
Q4 		$536K Buy
64,465
+6,665
+12% +$71.8K ﹤0.01% 3806
2025
Q3 		$843K Sell
57,800
-18,328
-24% -$219K ﹤0.01% 3470
2025
Q2 		$856K Buy
76,128
+28,712
+61% +$222K ﹤0.01% 3440
2025
Q1 		$270K Sell
47,416
-6,750
-12% -$68.8K ﹤0.01% 3886
2024
Q4 		$532K Buy
54,166
+42,224
+354% +$362K ﹤0.01% 3784
2024
Q3 		$97.3K Buy
11,942
+8,495
+246% +$85.1K ﹤0.01% 4582
2024
Q2 		$46.1K Sell
3,447
-6,227
-64% -$186K ﹤0.01% 4239
2024
Q1 		$449K Buy
9,674
+457
+5% +$23.7K ﹤0.01% 3663
2023
Q4 		$623K Sell
9,217
-166
-2% -$10.2K ﹤0.01% 3746
2023
Q3 		$679K Buy
9,383
+729
+8% +$58.3K ﹤0.01% 2600
2023
Q2 		$644K Sell
8,654
-11,001
-56% -$651K ﹤0.01% 2594
2023
Q1 		$1.05M Sell
19,655
-2,178
-10% -$138K ﹤0.01% 2700
2022
Q4 		$1.48M Buy
21,833
+2,754
+14% +$253K ﹤0.01% 2479
2022
Q3 		$2.38M Buy
19,079
+11,400
+148% +$1.36M ﹤0.01% 1629
2022
Q2 		$731K Buy
7,679
+6,693
+679% +$816K ﹤0.01% 2582
2022
Q1 		$159K Buy
+986
New +$192K ﹤0.01% 3557

Other funds holding DNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $106B AUM 2.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
J.M. Forbes & Co
J.M. Forbes & Co Boston, Massachusetts $1.33B AUM 21.14% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Exchange Traded Concepts
Exchange Traded Concepts Oklahoma City, Oklahoma $25.3B AUM 51.52% 1-Year Est. Return
PGCM
Prescott Group Capital Management Tulsa, Oklahoma $1.11B AUM 20.16% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Universal-Beteiligungs- und Servicegesellschaft
Universal-Beteiligungs- und Servicegesellschaft Frankfurt Am Main, Germany $65.3B AUM 33.78% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $184B AUM 51.71% 1-Year Est. Return

Barclays's DNA Position: Q3 2026 in Review

Barclays increased its Ginkgo Bioworks (DNA) stake by 1,607% in Q3 2026, buying an estimated $3.92M and bringing the position to 511,416 shares worth $6.56M. The position accounts for ﹤0.01% of the portfolio, ranked #1894.

Barclays first reported a position in DNA in Q1 2022 and has held it in 19 quarters since. 64 funds tracked by Wall St. Rank hold DNA as of Q3 2026.

  • Barclays held 511,416 shares of Ginkgo Bioworks worth $6.56M as of Q3 2026.
  • Barclays bought 481,450 Ginkgo Bioworks shares in Q3 2026, an estimated $3.92M.
  • Ginkgo Bioworks made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #1894 holding.
  • Barclays first reported a position in Ginkgo Bioworks in Q1 2022 and has held it in 19 quarters since.
  • 64 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.